The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
OneChain Immunotherapeutics (OCI), a Spanish biotech focused on the development of CAR-T therapies for the treatment of oncologic diseases, has named Stefanos Theoharis as the company's new chief executive. 1 February 2024
Clinical-stage US pharma company Protagonist Therapeutics' shares rose 6% to $26.5O in early trading, on news of a licensing deal for its blood disorder candidate rusfertide. 1 February 2024
French pharma major Sanofi was trading 4% lower late Thursday after presenting its fourth quarter and full year 2023 financial results. 1 February 2024
A new cell and gene therapy initiative from the USA's White House will launch with an initial focus on treatments for sickle cell disease (SCD). 1 February 2024
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
US clinical-stage biotech Remix Therapeutics today announced the appointment of Dominic Reynolds, as its chief scientific officer (CSO). 1 February 2024
Privately-held Scotland-based EnteroBiotix has announced the appointments of Dr James Barnes as chief operating officer (COO) and Chris Lea as chief financial officer (CFO). 1 February 2024
US biotech company Novavax, a specialist in protein-based vaccines, has detailed its latest plans for job cuts to save funds for the cash-strapped company. 1 February 2024
Adaptimmune Therapeutics saw its shares leap almost 10% by close of trading Wednesday and a further 5.2% to $1.01 in after-hours trading as it announced a regulator development for its cell therapy. 1 February 2024
China-based Innovent Biologics recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results. 1 February 2024
The UK’s health technology assessor the National Instituted for Health and Care excellence (NICE) has recommended Tepkinly (epcoritamab), from US pharma major AbbVie, as a treatment option for eligible adults with an aggressive and fast-growing blood cancer. 1 February 2024
The US Food and Drug Administration (FDA) yesterday released the Revised Biosimilar User Fee Amendment (BsUFA) Research Roadmap to provide updated information about the biosimilar regulatory science research pilot program research priorities. 1 February 2024
All ongoing clinical trials in the European Union (EU) must be transitioned to the Clinical Trials Information System (CTIS) by January 31, 2025. 31 January 2024
UK health assessor the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England and Wales recommending the use of Zynlonta (loncastuximab tesirine), from Swedish Orphan Biovitrum. 31 January 2024
Sandoz, the recent generic and biosimilar medicines spin out from Novartis , today announced the launch of Tyruko (natalizumab) in Germany from February 1. 31 January 2024
Danish diabetes care giant Novo Nordisk this morning released financial results for full year 2023, showing that sales increased by 31% in kroner and by 36% at constant exchange rates to 232.3 billion kroner ($33.9 billion) in 2023 31 January 2024
British drugmaker GSK has exceeded expectations in the fourth quarter, with chief executive Dame Emma Walmsley presenting an upbeat view of the company’s trajectory. 31 January 2024